SYS.PLAYERS
SN
Players/New Age Movement

ATAI Life Sciences + Compass Pathways — Psychedelic Capital Architecture

Founded 2018 / Series C Nov 2020 Thiel-led $125M / IPO April 2021 $100M

ATAI Life Sciences founded 2018 by Christian Angermayer, Florian Brand, Lars Wilde, and Srinivas Rao. Acts as the largest minority-share investor in Compass Pathways, the synthetic-psilocybin patent-developer.
Financial Trajectory: $24 million convertible note round welcoming Jason Camm of Thiel Capital to the Board. $125 million Series C closed November 2020, co-led by Apeiron Investment Group (family office of co-founder Christian Angermayer), Peter Thiel, and Catalio Capital Management. $100 million IPO April 2021 on Nasdaq under ticker ATAI.
Cumulative ~$225 million raised within ~3 years of founding — versus MAPS (the legacy non-profit psychedelic-research organization founded 1986) which raised roughly $20 million over the prior decade.
This Rapid capital velocity verifies the H4 transition from open-science / non-profit psychedelic research to patent-driven for-profit operator-class consolidation. Brings defense-tech and mass-surveillance capital (via Thiel) directly into the pharmacological-alteration substrate. Eclipses MAPS funding by an order of magnitude in a third of the time.